Other studies regarding upstream regulators of SIRT1, such as IRF9/PPAR-α, NAMPT/NMNAT, HuR, AMPK, PARP1, CK2 and cathepsins have pointed to these proteins as possible therapeutic targets for the treatment of various inflammatory pathologies, including liver diseases. Here, ELAVL1 is linked to liver disorder.